| Name | PCSK9-IN-11 |
| Description | PCSK9-IN-11 (compound 5r) is a potent PCSK9 inhibitor with oral activity, exhibiting inhibitory activity on PCSK9 transcription in HepG2 cells (IC50 = 5.7 μM) and capable of increasing LDL receptor (LDLR) protein levels. PCSK9-IN-11 is applicable for atherosclerosis research. |
| In vitro | PCSK9-IN-11 (compound 5r) (0-25 μM, 24 h) significantly reduces PCSK9 protein levels and increases LDLR expression in a dose-dependent manner[1]. |
| In vivo | PCSK9-IN-11 (compound 5r) (0-1000 mg/kg, gavage, once) demonstrates superior safety in vivo, with an LD50 value exceeding 1000 mg/kg. Administered at 30 mg/kg via gavage once daily for 8 weeks, PCSK9-IN-11 significantly inhibits liver PCSK9 expression and slightly reduces serum PCSK9 levels [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 3.82 mg/mL (10.01 mM), Sonication is recommended.
|
| Keywords | PCSK9-IN-11 | PCSK9IN11 | PCSK9 |
| Inhibitors Related | Imanixil | Compound T72025(SC) | Evolocumab | Propane-1,2,3-triyl tripalmitate | Coptisine | Pep 2-8 ammonium salt(1541011-97-5 free base) |
| Related Compound Libraries | Bioactive Compound Library | Inhibitor Library | Anti-Cardiovascular Disease Compound Library | Orally Active Compound Library | Lipid Metabolism Compound Library | Bioactive Compounds Library Max | Fluorochemical Library |
United States
